Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors within the central nervous technique, conolidine modulates alternate molecular targets. A Science Advancements review observed that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://randalla900tfp1.wiki-promo.com/user